{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T07:08:20Z","timestamp":1791011300179,"version":"4.1.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2007,6,26]],"date-time":"2007-06-26T00:00:00Z","timestamp":1182816000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Atheroscler Rep"],"published-print":{"date-parts":[[2007,7]]},"DOI":"10.1007\/s11883-007-0034-3","type":"journal-article","created":{"date-parts":[[2007,6,25]],"date-time":"2007-06-25T11:20:47Z","timestamp":1182770447000},"page":"281-285","source":"Crossref","is-referenced-by-count":6,"title":["Antiatherosclerotic effects of statins: LDL versus non-LDL effects"],"prefix":"10.1007","volume":"9","author":[{"given":"Andrew P.","family":"Selwyn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2007,6,26]]},"reference":[{"key":"34_CR1","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.1161\/CIRCULATIONAHA.106.655688","volume":"114","author":"V.J. Dzau","year":"2007","unstructured":"Dzau VJ, Antman EM, Black HR, et al.: The Cardiovascular Disease Continuum Validation; clinical evidence of improved outcomes: Part 1: pathophysiology and clinical evidence (risk factors through stable coronary disease). Circulation 2007, 114:2850\u20132870.","journal-title":"Circulation"},{"key":"34_CR2","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1161\/hc0902.104353","volume":"105","author":"P. Libby","year":"2002","unstructured":"Libby P, Ridker PM: Inflammation in atherosclerosis. Circulation 2002, 105:1135\u20131143.","journal-title":"Circulation"},{"key":"34_CR3","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1016\/j.jacc.2005.05.085","volume":"46","author":"J.G. Robinson","year":"2005","unstructured":"Robinson JG, Smith B, Maheshwari N, et al.: Pleiotropic effects of statins: benefit beyond cholesterol reduction? a meta-regression analysis. J Am Coll Cardiol 2005, 46:1855\u20131862","journal-title":"J Am Coll Cardiol"},{"key":"34_CR4","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2165\/00129784-200606020-00005","volume":"6","author":"B. Tesfamariam","year":"2006","unstructured":"Tesfamariam B: The effects of HMG-CoA reductase inhibitors on endothelial function. Am J Cardiovasc Drugs 2006, 6:115\u2013120.","journal-title":"Am J Cardiovasc Drugs"},{"key":"34_CR5","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1016\/j.jacc.2005.05.086","volume":"46","author":"K.R. Ray","year":"2005","unstructured":"Ray KR, Cannon CP: The potential relevance of the multiple lipid-independent (pleiotropic) effects of statins in the management of acute coronary syndromes. J Am Coll Cardiol 2005, 46:1425\u20131433.","journal-title":"J Am Coll Cardiol"},{"key":"34_CR6","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1161\/01.RES.0000236798.01988.5d","volume":"99","author":"J. Liao","year":"2006","unstructured":"Liao J: Rho-kinase: a potential link between hypercholesterolemia and abnormal vascular smooth muscle contraction. Circ Res 2006, 99:238\u2013239.","journal-title":"Circ Res"},{"key":"34_CR7","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1161\/01.ATV.0000176193.83629.c8","volume":"25","author":"H. Shimokawa","year":"2005","unstructured":"Shimokawa H, Takeshita A: Rho kinase is an important therapeutic target in cardiovascular medicine. Arterioscler Thromb Vasc Biology 2005, 25:1767\u20131775.","journal-title":"Arterioscler Thromb Vasc Biology"},{"key":"34_CR8","doi-asserted-by":"crossref","first-page":"C661","DOI":"10.1152\/ajpcell.00459.2005","volume":"290","author":"K. Noma","year":"2006","unstructured":"Noma K, Oyama N, Liao JK: Physiological role of ROCKS in the cardiovascular system. Am J Physiol Cell Physiol 2006, 290:C661\u2013C666.","journal-title":"Am J Physiol Cell Physiol"},{"key":"34_CR9","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1161\/01.RES.0000251668.39526.c7","volume":"99","author":"A. Nohria","year":"2006","unstructured":"Nohria A, Grunert M, Rikitake Y, et al.: Rho kinase inhibition improves endothelial function in human subjects with coronary artery disease. Circ Res 2006, 99:1426\u20131432.","journal-title":"Circ Res"},{"key":"34_CR10","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.jacc.2006.06.082","volume":"49","author":"K. Noma","year":"2007","unstructured":"Noma K, Goto C, Nishioka K, et al.: Roles of Rho-associated kinase and oxidative stress in the pathogenesis of aortic stiffness. J Am Coll Cardiol 2007, 49:698\u2013705.","journal-title":"J Am Coll Cardiol"},{"key":"34_CR11","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1161\/01.RES.0000196564.18314.23","volume":"97","author":"Y. Rikitake","year":"2005","unstructured":"Rikitake Y, Liao JK: Rho-GT pases, statins, and nitric oxide. Circ Res 2005, 97:1232\u20131235.","journal-title":"Circ Res"},{"key":"34_CR12","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1016\/j.jacc.2006.12.043","volume":"49","author":"P.Y. Liu","year":"2007","unstructured":"Liu PY, Chen JH, Lin LJ, et al.: Increased Rho-kinase (ROCK) activity in a Taiwanese population with metabolic syndrome. J Am Coll Cardiol 2007, 49:1619\u20131624.","journal-title":"J Am Coll Cardiol"},{"key":"34_CR13","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/j.jacc.2005.03.077","volume":"46","author":"K.K. Ray","year":"2005","unstructured":"Ray KK, Cannon CP, McCabe CH, et al.: Early and late benefits of high dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial. J Am Coll Cardiol 2005, 46:1405\u20131410.","journal-title":"J Am Coll Cardiol"},{"key":"34_CR14","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1001\/jama.291.9.1071","volume":"291","author":"S.E. Nissen","year":"2004","unstructured":"Nissen SE, Tuzcu EM, Schoenhagen P, et al.: Effects of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized control trial. JAMA 2004, 291:1071\u20131080.","journal-title":"JAMA"},{"key":"34_CR15","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1161\/01.CIR.0000164260.82417.3F","volume":"111","author":"U.F. Landmesser","year":"2005","unstructured":"Landmesser UF, Bahlman F, Meuller M, et al.: Simvastatin versus exenitide: pleiotropic and lipid lowering effects on endothelial function in humans. Circulation 2005, 111:2356\u20132363.","journal-title":"Circulation"}],"container-title":["Current Atherosclerosis Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-007-0034-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11883-007-0034-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-007-0034-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T23:35:31Z","timestamp":1559432131000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11883-007-0034-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,6,26]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007,7]]}},"alternative-id":["34"],"URL":"https:\/\/doi.org\/10.1007\/s11883-007-0034-3","relation":{},"ISSN":["1523-3804","1534-6242"],"issn-type":[{"value":"1523-3804","type":"print"},{"value":"1534-6242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,6,26]]}}}